Jo Christon
About Jo Christon
Jo Christon is the Associate Director Field Access at Bristol Myers Squibb, with extensive experience in market access and pharmaceutical sales.
Company: Bristol Myers Squibb
Jo Christon is currently serving as Associate Director Field Access at Bristol Myers Squibb. In this role, Jo is responsible for developing and executing strategies to enhance the accessibility of the company's pharmaceutical products in various regions. Jo previously worked at the same company as a Regional Access Manager from 2019 to 2021.
Title: Associate Director Field Access
As the Associate Director Field Access at Bristol Myers Squibb, Jo Christon manages a range of initiatives aimed at ensuring that patients and healthcare providers have timely access to groundbreaking treatments. This position involves close interaction with healthcare systems to facilitate optimal market conditions for new drug introductions.
Education and Expertise: Edinburgh Napier University
Jo Christon holds a Bachelor of Arts (BA) in Business Studies from Edinburgh Napier University, completed between 1992 and 1996. This educational background underpins Jo's expertise in developing innovative partnership solutions and navigating complex market conditions within the NHS and pharmaceutical sector.
Background: Extensive Experience in Pharmaceutical Sales and Market Access
Jo Christon has a robust career in the pharmaceutical industry, marked by significant roles such as Head of Sales at Boehringer Ingelheim (2016-2018) and Local Account Manager at Pfizer (2014-2016). Jo also served as Primary Care Sales Representative at Pfizer for 16 years. This extensive experience includes specializations in Cardiology, Diabetes, Respiratory, and Immuno-Oncology.
Specializations: Market Access and Healthcare Solutions
Jo Christon specializes in market access within the pharmaceutical industry, leveraging a deep understanding of healthcare systems to create win-win solutions for the NHS and patients. Jo's work is particularly focused on areas such as Cardiology, Diabetes, Respiratory, and Immuno-Oncology, aiming to improve patient outcomes through strategic partnerships.